Patrys LimitedASX: PAB

Appendix 4C - Quarterly - 31 March 2024

· Issued by Patrys Limited

Filed with ASX · · 8 pages · English

Summary by 6ix AI

The report highlights the successful completion of a GMP production run and positive preclinical data regarding the use of deoxymabs for treating autoimmune diseases. The report also outlines ongoing business development efforts and the establishment of a Master Cell Bank for further product development.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Patrys Limited on 6ix

Story so far

Earlier from Patrys

Later from Patrys

All Patrys news releases